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Abstract Science is idolized as a cumulative process (“standing on the shoulders
of giants”), yet scientific knowledge is typically built on a patchwork of research con-
tributions without much coordination. This lack of efficiency has specifically been
addressed in clinical research by recommendations for living systematic reviews
and against research waste. We propose to further those recommendations with
ALL-IN meta-analysis: Anytime Live and Leading INterim meta-analysis. ALL-IN
provides statistical methodology for a meta-analysis that can be updated at any
time—reanalyzing after each new observation while retaining type-I error guar-
antees, live—no need to prespecify the looks, and leading—in the decisions on
whether individual studies should be initiated, stopped or expanded, the meta-
analysis can be the leading source of information. We illustrate the method for
time-to-event data, showing how synthesizing data at interim stages of studies can
increase efficiency when studies are slow in themselves to provide the necessary
number of events for completion. The meta-analysis can be performed on interim
data, but does not have to. The analysis design requires no information about the
number of patients in trials or the number of trials eventually included. So it can
breathe life into living systematic reviews, through better and simpler statistics, effi-
ciency, collaboration and communication.
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The scientific response to the Covid-19 pandemic consti-
tutes a major gamble. In the US, for example, the funding
program for vaccine development did not put money on a
single vaccine, but on six different ones. They purposely
took “multiple shots on goal” according to Larry Corey
of the NIH Covid-19 Prevention Network in an interview
with STAT (Branswell, 2021). Vaccine development is not
a sure thing, and so their strategy needed to be robust
enough to just “let the chips fall”. Also in the search for
treatments, the scientific community had to hedge its bets.
Clinical trials competed for resources and patients, and
had to continuously change course when new informa-
tion arrived. In contrast to vaccines, however, in most
countries a strategy to find treatments was lacking. Many
clinical trials suffered from “poor questions, poor study
design, inefficiency of regulation and conduct, and non or
poor reporting of results”: research waste (Glasziou et al.,
2020). We believe that more strategic thinking can ben-
efit a future pandemic response as well as non-pandemic
evidence-based medicine, as uncertainty is often a given.
Honest scientific bets can breathe life into the approach
called living systematic reviews that aims to keep the evi-
dence record up-to-date (Elliott et al., 2017) and the med-
ical guidelines current (Akl et al., 2017). We propose to
make those bets by using ALL-IN meta-analysis in clinical
trial design, monitoring and reporting.
ALL-IN meta-analysis stands for Anytime Live and Lead-
ing INterim meta-analysis. The Anytime aspect provides
analysis that controls type-I error in testing and coverage
in interval estimation regardless of the decision making
along the way, and so regardless of any stopping rules
or accumulation bias processes (Ter Schure and Grün-
wald, 2019). The Live aspect prevents research waste
caused by meta-analyses that are out-of-date, which is
often the case in retrospective meta-analysis. The syn-
thesis can be a bottom-up collaboration of trials, as well
as a prospective top-down statistical analysis for decision
making. The Leading aspect allows the systematically col-
lected evidence included so far to drive the necessity and
design of new trials. Finally, the INterim aspect is new
in meta-analysis and makes for effortless combination of
trials while they are still ongoing. What is more, ALL-
IN meta-analysis is also literally ALL-IN since any number
of new studies can be included; it has an unlimited hori-
zon. We illustrate this in the setting of time-to-event data,
where waiting for new events is an inherent challenge of
clinical trials. Combining trials early can prevent delays if
studies are slow in themselves to complete the necessary
number of events. ALL-IN has advantages in four cate-
gories: statistics, efficiency, collaboration and communi-
cation. We introduce all four briefly (page 4-5) before
we go into more detail, but first illustrate the language of
betting for single trials studying a Covid-19 vaccine.
A single trial: the FDA game
On June 30th, 2020, the US Food and Drug Administra-
tion (FDA) published its guidance document on “Devel-
opment and Licensure of Vaccines to Prevent Covid-19”
(FDA, 2020). This set the goals for any Phase III clini-
cal trial betting on a protective effect of a vaccine against
Covid-19. The guidance document advised on the defi-
nition of events of confirmed (symptomatic) SARS-CoV-2
infection for the trials to be counting. And in counting
those, the document prescribed the two things to achieve:
(1) at least a vaccine efficacy (VE) of 50% and (2) evi-
dence against a null hypothesis of ≤ 30% VE (FDA, 2020,
p. 14). Most Covid-19 vaccine trials randomized large
numbers of participants 50:50 vaccine:placebo such that
we can assume that also throughout the trial the partici-
pants at risk stayed approximately balanced. According to
the definition of SARS-Cov-2 infections, we start counting
once a participant has a confirmed infection after being
fully vaccinated for at at least a number of days (e.g. 7
days in the Pfizer-BioNTech trial (Polack et al., 2020))).
This is also when a (virtual) bet could start. In the fol-
lowing we reinterpret the design for the Covid-19 vaccine
trials in the language of betting.
Each new event carries evidence that we express by a bet-
ting score. We make a (virtual) investment on one of the
two outcomes: either the next event occurs in the vac-
cine group or it occurs in the placebo group. If there is
no effect of the vaccine whatsoever, the 50:50 risk set en-
sures that the infected participant has 0.5 a chance to be
vaccinated and 0.5 a chance to be a placebo. Yet, fol-
lowing the FDA, we do not only want to rule out an in-
effective vaccine, but also reject the hypothesis that the
vaccine has an effect that is too small—set as the null hy-
pothesis of (at most) 30% VE. In that case each newly
observed infection has slightly smaller chance to be a vac-
cinated participant. That probability to be in the vaccine
group is 0.41, since each placebo group member has a
100% risk of Covid-19 and a vaccine group member has
100−30= 70% of the risk, which is a fraction 0.41 of the
total risk (70/(100+ 70)). So if the VE is too small to be
of interest we expect (at least) a fraction 0.41 of Covid-19
events to occur in the vaccine group and (at most) 0.59
in placebo.
How do we bet against that and win if the vaccine has a
much larger protective effect? We are betting against the
probability 0.41 of the next Covid-19 event to occur in the
vaccine group. If this probability actually is that large (the
vaccine is not very protective; the null hypothesis) we do
not want the game to be favorable under any strategy, just
like the casino does not want any gambler to earn a salary
playing the roulette wheel. On the other hand, we are bet-
ting in favor of a much smaller probability for the vaccine
group. If this probability is smaller (the vaccine is protec-
tive; the alternative hypothesis) we do want to win money,
just like a professional poker player who makes a salary
out of gambling well. We use the betting scores to de-
cide whether the vaccine is a real deal-breaker (the scores
behave like the salary of a professional poker player) or
whether it is not effective enough (the scores behave like
anyone playing the roulette wheel). To ensure that our
betting scores can show either case, we first design the
game such that it is fair—under the null hypothesis—and
then optimize playing the game with a strategy that is prof-
itable —under the alternative.
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Designing a fair game under the null hypothesis Con-
sider gambling at the roulette table where the vaccine
trial analogy is like betting on red (vaccine) or black
(placebo). Betting correctly doubles your investment,
betting incorrectly loses everything you risked. Assum-
ing no house edge and an initial =C100 you do not ex-
pect to increase your investment, since you have 0.5 a
chance of doubling (2 · =C100) and 0.5 a chance of los-
ing all (0 · =C100). Whether you bet everything on black
or red, in expectation the betting score after one round is
(0.5·2+0.5·0)·=C100, which is the initial investment =C100.
To achieve the same thing betting against the 0.41:0.59
probabilities instead of 0.5:0.5, your investment needs
to multiply by 2.4 (1/0.41) for vaccine and 1.7 (1/0.59)
for placebo. If you bet everything on vaccine you have
0.41 chance of multiplying by 2.4 (2.4 · =C100) and 0.59
chance of losing all (0 · =C100) and if you bet everything
on placebo you have 0.59 chance of multiplying by 1.7
(1.7 ·=C100) and 0.41 chance of losing all (0 ·=C100). The
expected betting score after one round is again the ini-
tial investment for both: (0.41 · 1/0.41+ 0.59 · 0) · =C100
and (0.59 · 1/0.59+ 0.41 · 0) · =C100. Hence, at either the
roulette table or in this FDA game, by design the game
is fair and not favorable us. After all, if our observed in-
fections land on the vaccine and control group with the
probabilities 0.41:0.59—like a spin of the roulette wheel
on black and red with 0.5:0.5—we do not expect to claim
an effective vaccine.
Optimize playing the game under the alternative hy-
pothesis How do we win as fast and as much as possi-
ble if our observed infections do not behave like a roulette
wheel? It has been known since the work of Kelly (1956)
and Breiman (1961) that the best way to increase your
capital in the long run is to not bet all your (virtual)
investment =C100 on one of the two possible outcomes
(red/vaccine or black/placebo) but to divide it based on
the odds that make the game favorable to you. So our fo-
cus needs to be on the minimal VE of 50% from the FDA
guidance. In the scenario of 50% VE, the probability that
the next Covid-19 case is in the vaccine group is 1/3: if
we set the risk of Covid-19 for a placebo group member
to 100%, a vaccine group member has 100−50= 50% of
that risk, which is 1/3 of the total risk (50/(100 + 50)).
Kelly (1956) and Breiman (1961) urge us to invest one-
third (1/3 · =C100) on observing the next infection in the
vaccine group and two-thirds (2/3 · =C100) on placebo.
Likelihood ratios If we bet this way we can rewrite our
betting scores in terms of a likelihood ratio. We first show
this for the red-black roulette game where we double
what we had put at risk on either black or red if the spin
of the roulette wheel outputs the color we bet on. Just
like in our strategy in the FDA game, we put 1/3 · =C100
on red and 2/3 · =C100 on black, so we win the following
if the ball X lands on either red or black:




L (1/3 | X )
L (1/2 | X )
· =C100




L (1/3 | X )
L (1/2 | X )
· =C100
The Bernoulli 1/3-likelihood L (1/3 | X ) assigns likeli-
hood 1/3 when is X = red and 2/3 when is X = black. So
if our strategy is to invest 1/3-2/3 in roulette, our payout
is our initial investment =C100 multiplied by the likelihood
ratio, whether X is red or black.




L (50% VE | X )
L (30% VE | X )
· =C100




L (50% VE | X )
L (30% VE | X )
· =C100
The likelihood for 50% VE (L (50% VE | X )) assigns
likelihood 1/3 when is X = vaccine and 2/3 when is
X = placebo. Similarly, the likelihood for 30% VE
(L (30% VE | X )) assigns likelihood 0.41 when is X =
vaccine and 0.59 when is X = placebo. Hence if our
strategy is to invest 1/3-2/3 in the FDA game, our pay-
out is also our initial investment =C100 multiplied by the
likelihood ratio, whether X is vaccine or placebo.
A winner The Pfizer/BioNTech trial observed 8 cases of
Covid-19 among participants assigned to receive the vac-
cine and 162 cases among those assigned to placebo (Po-
lack et al., 2020). We assume now that we start with an
initial (virtual) investment of =C1 instead of =C100. At the
first observation we bet =C0.33 on vaccine and =C0.66 on
placebo. After we observe the event in the placebo group
we lose our =C0.33 bet on vaccine and multiply our =C0.66
on placebo by 1.7 to =C1.13. The likelihood ratio between
our 30% VE alternative hypothesis and our 50% VE null
hypothesis—so L (50% VE | X )/L (30% VE | X )—is also
about 1.13, so multiplying our initial investment of =C1
into =C1.13. On the other hand, if we observe the event
in the vaccine group we lose our =C0.66 bet on a placebo
event and multiply our =C0.33 on vaccine by 2.4 to =C0.81.
The likelihood ratio of a vaccine event multiplies our in-
vestment by 0.81. After each observed event we reinvest
what we have left in the new bet, so multiply that with
the next likelihood ratio. With 8 cases vaccine and 162
cases placebo the Pfizer/BioNTech publication could re-
port a total betting score of 0.818 · 1.13162· =C1, which is
about =C118 million (note that 1.13 is really 1.13333 . . .).
If someone wins that at the poker table, we have good
reason to consider her a professional poker player with
a favorable strategy, rather than a lucky beginner (Kon-
nikova, 2020).
Meta-analysis: bottom-up collaboration
The Pfizer/BioNTech trial included more than 43 thou-
sand participants (Polack et al., 2020), which is quite
unique for a clinical trial. Usually trials are much smaller,
and scientific consensus is built through systematic re-
views and retrospectively combining trials in a meta-
analysis. ALL-IN is a way to do so by collaborating
bottom-up in a strategic way that can be live instead of
retrospective. It has advantages in four categories that
we will first briefly introduce and then further elaborate
on in this paper: statistics, efficiency, collaboration and
communication.
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Statistics
Not all mRNA vaccines showed such favourable results as
the Pfizer/BioNTech vaccine. In a press release CureVac
AG (2021) announced that the final analysis of their clin-
ical trial observed 83 events in the vaccinated group and
145 in placebo, so only a 43% VE1 (our calculations as-
suming a 50:50 balanced risk set (r = 1 in CureVac AG
(2020, p. 124))). Their protocol states the FDA goal
in terms of a confidence interval that excludes a VE of
30%, adjusted for two interim analyses. That adjusted
confidence interval at the final analysis is based on Zα/2-
statistic for the nominal level α/2 = 0.02281 (CureVac
AG, 2020, Table 8). That interval is [25.3%, 57.1% VE]
(our calculations; normal approximation interval) and,
regrettably, does not exclude 30%. When the chips fell,
this trial lost.
Statistical analyses like these are essentially all-or-
nothing, just as any other p < α analysis. As soon as
all the α is spent—either on a few interims and a final
analysis or just on one fixed sample size—we cannot con-
tinue the trial and perform subsequent analyses without
violating the type-1 error rate. This might be a reasonable
price to pay in the urgency of a pandemic when multiple
vaccines are competing, but it is a very inconvenient prop-
erty for clinical trials in general. Usually, we do want to
reanalyze a clinical trial in combination with other simi-
lar trials in a meta-analysis. Yet any p < α procedure is
equivalent to setting a rejection region for the test statis-
tic and checking whether the value for the statistic falls
within that region. This rejection region is based on a
sampling distribution that assumes the number of studies
in the meta-analysis, and the number of patients within
each study to be fixed in advance. Given such a fixed sam-
ple size (but also for any sequential stopping rule that sets
a maximum sample size in advance, such as α-spending),
there is only one region, and your test statistic is either in
it or not. If it is not, you are not allowed to redo the analy-
ses with an increased sample size. This problem is recog-
nized in approaches to control type-I error for living sys-
tematic reviews (Simmonds et al., 2017). But also if the
meta-analysis is not updated (often), the α is essentially
already spent on the individual trial analyses. A different
way to see this is by the actual sampling distribution of tri-
als in a meta-analysis: any data-driven decision within the
series—whether to accumulate more studies and when to
perform the meta-analysis—changes the sampling distri-
bution and invalidate the fixed-sample-size distribution
assumed for p < α. Hence hardly any meta-analysis has
valid type-I error control, when the accumulation of trials
is based on strategic decisions that introduce accumula-
tion bias (Ter Schure and Grünwald, 2019).
ALL-IN meta-analysis is not all-or-nothing but can still
combine all available studies. In fact, it allows any num-
ber of new studies or patients to be included without ever
spending all α. In terms of gambling, we can keep betting
our virtual investment because we never lose everything.
1The CureVac AG (2021) press release reports a VE of 48%, so uses a
different r (ratio of follow-up time in the two groups). In such large trials
r can often be assumed to stay close to 1, so we set it to 1 to make all
calculations simpler. All our calculations can be found via Appendix B.
The CureVac AG (2021) results, for example, would have
accumulated a betting score of 0.8183 · 1.13145· =C1 =
=C1.84. This single trial is not very profitable, but at least it
still preserves some evidence to reinvest in the next trial,
such that we can continue to observe evidence and ex-
press it by betting on additional observations in a new
trial. An ALL-IN meta-analysis can always continue test-
ing the null hypothesis—with type-I error control—and
estimating the confidence interval—with coverage guar-
antees. Importantly, for these tests and intervals the pro-
cedures are exactly the same no matter what decisions—
so-called stopping rules, or accumulation bias processes
(Ter Schure and Grünwald, 2019)—are at play.
Efficiency
Lack of efficiency has been addressed in clinical research
in many ways. Not only in the proposal of living sys-
tematic reviews (Elliott et al., 2017), but also in encour-
agements to present new studies in the context of ex-
isting evidence (Young and Horton, 2005), in advice to
design new trials based on systematic reviews and meta-
analysis (Chalmers and Lau, 1993; Lau et al., 1995; Sut-
ton et al., 2007; Goudie et al., 2010; Lund et al., 2016)
and in pleading to prevent the “scandal” of wasteful re-
search into clinical questions that are already answered or
not of primary importance (Altman, 1994; Chalmers and
Glasziou, 2009; Glasziou and Chalmers, 2018; Glasziou
et al., 2020, “research waste”). These calls have not been
completely ignored, since clinical research has seen an in-
crease in efficiency—e.g. in platform trials or adaptive
meta-analysis (Tierney et al., 2021)—whenever collab-
oration is deemed possible prospectively. Nevertheless,
most clinical trial data is synthesized retrospectively, and
still deserves all of the above recommendations. ALL-
IN meta-analysis enables these data-driven decisions that
can make science more efficient. New studies can be eas-
ily informed by the synthesis of all data so far such that
exactly the right number of patients are randomized to an-
swer a research question, no more and no less. Moreover,
an ALL-IN meta-analysis can give an account of the evi-
dence at anytime and therefore facilitate prioritizing new
studies, if more than one line of research needs additional
data, but not all can be funded.
Collaboration
ALL-IN meta-analysis can be a live meta-analysis, since it
does not matter how many studies will eventually be com-
bined or which study will contribute most data. Whether
it is based on summary statistics (Tierney et al., 2021) or
on individual patient (IPD) data (Polanin and Williams,
2016), involvement in the same meta-analysis facilitates
discussion between those running trials in the same line
of research; especially if the line of research can be con-
cluded early. Trial protocols and statistical analysis plans
can be exchanged and scrutinized, to identify discrepan-
cies between the design and the conduct of trials. In an
ongoing meta-analysis, trials can be selected for inclusion
before investigators are unblinded to the results, which
helps to mitigate the problems of publication bias and
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p-hacking. If IPD analysis is possible, intense collabora-
tion might also prevent mistakes and fraudulent data that
would otherwise depreciate the meta-analysis.
A meta-analysis benefits from homogeneity. With too
much heterogeneity, it can be very disheartening to up-
date a random-effects meta-analysis, since many trials
are needed to precisely estimate the between trial varia-
tion and overcome it (Sutton et al., 2007; Kulinskaya and
Wood, 2014; Jackson and Turner, 2017). Close collab-
oration might prevent unnecessary heterogeneity, if trial
investigators are involved in the selection of trials in the
meta-analysis; especially if they can advise on the design
and conduct of new trials and align inclusion criteria and
endpoint definitions. A fixed-effects meta-analysis can
conclude the research effort early. Sufficient homogeneity
may be possible in close collaboration.
Communication
The language of betting The interpretation of evidence
in terms of a betting score might help to communicate the
uncertainty in statistical results. As Shafer (2021) puts it:
“When statistical tests and conclusions are framed as bets,
everyone understands their limitations. Great success in
betting against probabilities may be the best evidence we
can have that the probabilities are wrong, but everyone
understands that such success may be mere luck.” Think-
ing in terms of bets also helps to understand when statisti-
cal analyses can be anytime-valid. If they are of the all-or-
nothing kind, but reanalyzed in a meta-analysis, they are
gambling while broke. (This intuition can be made math-
ematically precise; see the description of Neyman-Pearson
testing in terms of betting Shafer (2021) and Grünwald
et al. (2019).) Yet if we add new studies to an ALL-IN
meta-analysis, we are reinvesting the betting score that
we saved from earlier studies, to evaluate whether the
strategy in those earlier studies continues to succeed. Just
like when reinvesting your profits in a casino from one
slot machine into another, the notion of winning stays the
same. Our evidence against the hypothesis of a fair casino
does not change when we alternate slot machines. It does
not change if we use the score so far to decide on alter-
nating them or to decide when to cash out. If the slot
machines are fair, any strategy of playing them is not ex-
pected to make money, and our notion of type-I error con-
trol holds under any dependency on past results (stopping
rules or accumulation bias processes).
Other communication Those uncomfortable with the
language of betting can also easily resort to any of
three more familiar notions of statistical communication.
Firstly, the likelihood ratios/betting scores and their gen-
eralizations, so-called e-values (Grünwald et al., 2019;
Vovk and Wang, 2021), can be interpreted as conservative
p-values by taking their inverse. If we denote any betting
score or e-value by € (e.g. € = =C1.84 for the CureVac
trial data), then p < 1/€ is a conservative p-value (e.g. p
= 1/1.84= 0.54 for the CureVac trial data). If we commu-
nicate the p-value p = 1/€ anyone can test by comparing
p < α but with the addition that this conservative p-value
is anytime valid2 and so p < α can never spend all α (it
is never an all-or-nothing test). Secondly, the likelihood
ratios have their own notion of evidence in the likelihood
paradigm (Royall, 1997). Just as well as stating that the
Pfizer/BioNTech trial (Polack et al., 2020) multiplied =C1
to almost =C118 million and the CureVac AG (2021) trial
multiplied =C1 to =C1.84, we can state that their data was
almost 118 million times and 1.84 times more likely if we
assume the FDA’s goal of 50% VE in comparison to as-
suming only 30% VE. For Pfizer, that sounds very good,
for CureVac, not so much, and so these numbers have an
interpretation of their own without imposing any α level.
Thirdly, likelihood ratios can be accepted by the Bayesian
paradigm, as Bayes factors, and possibly combined with
prior odds. Grünwald et al. (2019) and Grünwald (2021)
show that betting scores/e-values and Bayes factors are
closely related, although not all Bayes factors are betting
scores/e-values. The bottom-line for communication pur-
poses is that the reporting by ALL-IN meta-analysis can
be interpreted in many ways—p-values, likelihood ratios,
Bayes factors—but regardless of the interpretation pro-
vide fully frequentist type-I error control for tests and cov-
erage for confidence sequences.
The remainder of this paper discusses the four cate-
gories of advantages in more detail: Statistics in Sec-
tion 1, Efficiency in Section 2, Collaboration in Section 3
and Communication in Section 4. We use the Covid-
19 vaccine trials as running examples, based on the
FDA game described already, but also in terms of the
safe/e-value logrank test (Ter Schure et al., 2020b). We
also briefly discuss an actual ALL-IN meta-analysis in
Section 3.1, that used this safe/e-value logrank test to
study whether the BCG vaccine could protect against
Covid-19 (Van Werkhoven et al., 2021, ALL-IN-META-
BCG-CORONA). In the concluding section we will provide
some broader context, with an overview of all the meth-
ods already developed—e-values, safe tests (Grünwald
et al., 2019) and anytime-valid confidence sequences—
methods already available in software—notably safestats
R package (Ly et al., 2021)—and future work. R code for
all calculations, simulations and plots is online available
via Appendix B.
1 Statistics
The language of betting comes with the intuition that
winning a large betting score has small probability if the
null hypothesis is generating our observations (e.g. the
roulette wheel is fair). We will make this intuition precise
and show how to control the type-I error by bounding this
probability by Markov’s inequality and Ville’s inequality.
Crucial here is that the betting score underlying our test
is an e-value. The language of betting also comes with
the intuition that when playing a game that is favorable
to us in principle, we can use strategies of different qual-
ity: even among all strategies under which we expect to
get richer, some of them can be expected to earn us much
2Such conservative p-values cannot be pictured as the tails of a sam-
pling distribution since such a picture needs a sample size. Appendix A
gives more details.
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Simulated betting scores € / LR(n)  over betting rounds (events) n under the null hypothesis of 30% VE
Figure 1. 1000 simulated betting scores in the FDA game over betting rounds n assuming a probability of 0.41 (70/170)
for each event to occur in the vaccine group (the null hypothesis of 30% VE). The dashed line is the threshold 1/α= 40
one-sided. The histogram at the right shows the betting score/LR(170) after 170 events. Note that the expectation of 1
of the scores is not the mode of its distribution nor its median and that the y-axis is on a log scale.
more than others. We will relate the more well known
notion of power to such a different notion of optimality.
In the following we discuss both e-values and optimality
first for a single trial (in the FDA game and more gen-
erally) and then for ALL-IN meta-analysis. We conclude
by a generalization of optimal e-value tests to confidence
sequences.
1.1 Under the null: e-values in a single trial
To make the FDA game fair we imposed a multiplication
by 2.4 (or 170/70) if we observe the event in the vac-
cine group and 1.7 (or 170/100) if we observe it in the
placebo group. This multiplication has expectation 1 (or
smaller) if we assume the null hypothesis of a vaccine
with negligible VE of 30% (or smaller). In case of 30%,
we have probability 0.41 (or 70/170) to observe a vac-
cine event and probability 0.59 (or 100/170) to observe
placebo, so in expectation we multiply our investment by:
70/170 · 170/70 + 100/170 · 170/100 = 1. No matter
how we invest in the two outcomes, (e.g. putting 1/3 on
vaccine and 2/3 on placebo, or something different) in
expectation under the null we multiply the initial invest-
ment by 1. This means that our betting score is an e-value,
since by definition an e-value is the outcome of a nonneg-
ative random variable with expectation 1 under the null
hypothesis (Grünwald, 2021).
Our betting score could also be rewritten as a likeli-
hood ratio, so the expectation of the likelihood ratio
(L (50% VE | X )/L (30% VE | X )) is 1 as well. We hence-
forth write the likelihood ratio after n rounds of betting






L (50% VE | X i)
L (30% VE | X i)
. (1)
Using its expectation of 1, Markov’s inequality bounds the
probability of observing a large multiplication of our in-
















Figure 1 shows at the right side the histogram of bet-
ting scores in the FDA game after 170 events when we
simulate events under the null hypothesis, with proba-
bility 0.41 to occur in the vaccine group, corresponding
to 30% VE. A line is shown at 40, and indeed no more
than α = 1/40 = 2.5% of the scores seem to be larger
than that threshold. In fact, in these 1000 runs of simula-
tion only 0.3% of the runs have betting score larger than
40; Markov’s inequality is a loose bound. We also have
a stronger result because we obtained our betting score
over events by multiplying the score of the rounds (see
(1), corresponding to reinvesting our winnings), called
Ville’s inequality. We get the following from Ville (1939):
P30% VE

LR(n) ≥ 1/α for some n

≤ α.
Ville’s inequality is also illustrated in Figure 1: if we take
the sequence of rounds into account, still only a few out
of the 1000 simulations ever reach a betting score larger
than 40. In fact, in these 1000 runs of simulation only
1.1% of the runs have a betting score that is larger at any
round in the game, such that our type-I error is controlled
at α = 2.5% at any time. Moreover, this type-I error con-
trol is not tied to this maximum number of 170 events, but
continues to hold with an unlimited horizon. If the game
is fair, no strategy exists that would allow the player to
win forever (Ville (1939, p. 89, “ne gagne pas ind éfin-
imnt”) as cited by (Shafer, 2020)). Making a large profit
in such a fair game casts doubt on the null hypothesis and
is captured by a likelihood ratio that grows away from 1:
a large betting profit is obtained if the null likelihood is
performing worse than alternative.
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When trials can be summarized as bets Before they
can be combined in a meta-analysis, individual trials are
often characterized by the summary statistics from trial
publications. Conventional meta-analysis combines these
statistics (e.g. mean differences and standard deviations)
in a Z-statistic (Borenstein et al., 2009). Unlike the vac-
cine/placebo outcomes that we have seen so far, such a
Z-statistic has a continuous density and cannot be sum-
marized by separately dealing with all possible outcomes.
Fortunately, Shafer (2021) shows that any likelihood ratio
of distributions can be viewed as a betting score in a game
with initial investment =C1. This is possible because like-
lihood ratios have expectation 1 in general if we assume
the null hypothesis in the denominator of the ratio. For
a Z-statistic we have two normal distributions with vari-
ance 1, one with mean µ0 under the null hypothesis, and
one with µ1 under the alternative. If the data is generated


















which is 1 since φµ1(z) is a probability density that inte-
grates to 1. This means that any such likelihood ratio for a
Z-statistic is an e-value and can be used to construct tests
by betting.
Not all summary statistics can be assumed to form a Z-
statistic with a normal distribution. Fortunately for the lo-
grank statistic this is reasonable (Ter Schure et al., 2020b)
if studies are large and the effect size not too extreme
(hazard ratios not too far away from 1). We will use the
logrank Z-statistic as a running example for meta-analysis
on summary statistics. For an IPD meta-analysis (on in-
dividual patient data), however, we recommend to use
the exact safe/e-value logrank test from Ter Schure et al.
(2020b) that is valid regardless of the randomization (e.g.
1:1 balanced or 1:2 unbalanced), the number of partic-
ipants at risk, the number of events or the size of the
effect—so also for a hazard ratio 0.05 that corresponds
to a VE of 95%.
1.2 Under the null: e-values in a (live) meta-
analysis
Assume we want to perform a meta-analysis and we col-
lect a Z-statistic Zi from each trial i, e.g. a logrank
statistic. Before observing Zi we construct an honest bet
LRi = φµ1(Zi)/φµ0(Zi) for each trial that is an e-value
and thus has type-I error control under the null hypothesis
φµ0—for a default logrank statistic this is always µ0 = 0
corresponding to hazard ratio of 1. If we think of the
betting score from the first study and invest it in the sec-
ond study, we are in fact multiplying likelihood ratios. We
need to have a notion of time t, such that at each time we
know the number of studies k〈t〉 so far and the number of
observations ni〈t〉 in each study i. If we assume that all
studies are completed at time t with n1, n2, . . . , ni events
summarized by logrank Z-statistics z(n1)1 , z
(n2)
2 , . . . , z
(nk)
k we




















The global null hypothesis Each trial bet is testing the
same null hypothesis µ0 = 0 in (3), such that the ALL-
IN meta-analysis bet tests a global null hypothesis of no
effect (0% VE) in all trials. Such a global null hypothesis
can be rejected with a contribution from each trial, but
also in case only one trial observes a large score betting
against the hypothesis and no other trial observes a very
small betting score that loses those winnings again. After
all, the null in each trial is rejected as soon as the null is
rejected in one of the trials.
Meta-analysis on interim data We can generalize this
ALL-IN meta-analysis bet of completed trials to bets
on interim data by assuming that we only have an
interim logrank Z-statistic z1〈t〉, z2〈t〉, . . . , zk〈t〉 for the
n1〈t〉, n2〈t〉, . . . , nk〈t〉 events observed so far at time t;
k〈t〉 still represents the number of studies so far at time
t, but now these studies are not (all) completed. We con-


















From the perspective of Ville’s inequality, the analysis on
completed trials and the one on interim data are indistin-
guishable. The only thing that matters is that we include






≥ 1/α for some t

≤ α, (5)
for the global null hypothesis probability P0 with an un-
limited horizon over time t.
1.3 Under the alternative: optimality in a single
trial
A power analysis sets a very specific goal for a trial, usu-
ally to detect an effect of minimal clinical relevance. This
is the effect we would not like to miss if it were there,
although we hope that the real effect is larger. We nev-
ertheless use this smallest effect of interest to decide on
the sample size of the trial, otherwise we risk a futile trial.
The FDA was clear on what this minimal effect should be
for the Covid-19 vaccine trials: a VE of 50% (FDA, 2020).
This is the effect we used to bet in the FDA game.
Our strategy in the FDA game, however, was not try-
ing to achieve optimal power. If we compare the all-or-
nothing confidence interval for CureVac AG (2021) from
the introduction—the final analysis on 83+145 events—
we notice that this confidence interval [25.3%, 57.1% VE]
is smaller than the final anytime valid interval we show
in Figure 3 in Section 1.5, which is Note that we are com-
paring a Zα/2-confidence interval for α/2= 0.02281 with
α/2 = 0.05, so the wider interval cannot be attributed to
the level of α. The difference is that the former one is
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optimized to have spent all α at the final analysis, while
the latter one is optimized to continue data collection.
Power is the probability of finding the desired result us-
ing the specified analysis at a sample size or stopping
rule. So for an analysis that is intended to have unlim-
ited horizon, power is not a well-defined concept. In-
stead Grünwald et al. (2019) introduced the concept of
growth-rate optimality in the worst case, or GROW. Here,
the goal is to optimize the expected rate at which the
evidence grows (or the interval shrinks) for each new
data point, not at a specific sample size. The worst case
here is the 50% VE for a one-sided alternative hypothesis
H1 = {PVE : 50% ≤ VE ≤ 100%}. We optimized the FDA
bet in the introduction by putting this 50% VE in the al-
ternative likelihood. This can be rewritten in terms of a





L (50% VE | X i)
L (30% VE | X i)
=
L (50% VE | X1, . . . , Xn)










with µmin = log(0.5)/4 and µ0 = log(0.7)/4 with 0.5 and
0.7 the hazard ratios corresponding to VE of 50% and 30%
respectively (see Ter Schure et al. (2020b)). So our one-
sided alternative hypothesis for the logrank Z-statistic is
a Z-distribution with a mean representing an effect that
is at least µmin:
H1 = {φµ1 : µ1 ≤ µmin}
(since positive VE corresponds to a negative µ1). Our
choice of the parameter of the alternative likelihood µmin
follows directly from the minimal effect set by the FDA.
Kelly (1956) already showed that this way of betting op-
timizes the way our betting score grows if the true VE is
50% (our worst-case scenario). Breiman (1961) showed
that this approach also minimizes the number of events
we need to reach a given betting score set in advance
(e.g. =C1/α), for which some intuition is given in Figure 2.
Grünwald et al. (2019), Shafer (2021) and Ter Schure
et al. (2020b, Online Appendix) give various other rea-
sons why this is the best way to bet, relating it to data
compression, information theory, Neyman-Pearson test-
ing, Gibb’s inequality, and Wald’s identity. Most crucial
property for the purposes of ALL-IN meta-analysis is that
the alternative likelihood puts some money on each pos-
sible outcome, such that no matter what outcome we ob-
serve, we keep some of the money we risk. This contrasts
the approach with a classic p < α test that essentially puts
all money on the rejection region, such that if the outcome
is not in it, we we lose all and cannot continue betting. A
thorough interpretation of Neyman-Pearson testing and
p-values in terms of betting is given by both Grünwald














Expected N needed to achieve 1 α = 40
Figure 2. Nα is the expected number of events needed
to reach a betting score of 1/α = 40 for α = 0.025 if we
bet according to VE1 indicated by the three different lines,
with bets each of the form
∏N
i=1
L (VE1 |X i)
L (30% VE |X i)
. The number
of events we need decreases if the true VE underlying the
data increases (the true difference in risk between vaccine
and control is larger). The smallest number of events for
a true VE of 40% is reached by betting VE1 of 40% (blue
solid line), the smallest number of events for a true VE
of 50% by betting VE1 of 50% (orange dotted line) and
the smallest number for true VE of 60% by betting VE1 of
60% (grey dashed line). Note that for the alternative in
the FDA game H1 = {PVE : 50% ≤ VE ≤ 100%} we are
only interested in playing the game well if the true VE is
50% or larger. Since for larger true VE, taking VE1 = 50%
performs quite well, our strategy is to optimize for the
worst case of 50% VE itself and use the bet with VE1 =
50% in the FDA game.
1.4 Under the alternative: optimality in a meta-
analysis
ALL-IN meta-analysis allows for a retrospective meta-
analysis that is bottom-up. The betting score that we
accumulate by reinvesting from one trial into the other
(which is multiplying betting scores) has an interpreta-
tion without enforcing a common design or stopping rule
on all included trials. This is especially important if trials
have their own stopping rules, or if meta-accumulation
processes are at play that influence the existence of trials
based on earlier (trial) results in the same meta-analysis.
While a meta-analysis can be bottom-up and each have its
own design and effect of minimal interest, it can be advis-
able to agree on a µmin for the meta-analysis. However,
the meta-analysis betting score can also allow each trial
i to have its own alternative likelihood with parameter
µmin(i). Then the following multiplication of those betting
















As long as φµmin(i)pni is a probability density that integrates
to 1, we have that each likelihood ratio integrates to 1 un-
der the global null hypothesis, such that (5) holds. This
means that trials can also learn their parameter µmin(i)
from already completed trials. This is sometimes the case
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if trials are not powered to detect an effect of minimal in-
terest, but an effect that is plausibly true based on earlier
research. Kulinskaya et al. (2016) shows that such use
of existing studies to power new trials can actually bias
conventional meta-analysis since it introduces yet another
dependency between sample size and results that is unac-
counted for in any analysis that assumes a fixed sample
size. For ALL-IN meta-analysis this is no problem at all,
and trials can learn from each other as long as the param-
eter µmin(i) is fixed before seeing new data that is eval-
uated using that parameter in (7). In Ter Schure et al.
(2020b) we discuss the advantages of even learning the
parameter within one trial using prequential plugins or
Bayesian posteriors. In a game like the FDA game with a
clear goal, this is inferior to the GROW approach, but in
other situations it could be preferred.
1.5 Confidence sequences
The CureVac AG (2021) trial reached their final interim
analysis but was not able to reject the null hypothesis of
30% VE. The trial had been too optimistic and powered for
60% instead of 50% VE (CureVac AG, 2020). If a trial is
underpowered but still has a large number of participants
in follow-up, there is good reason to continue the trial, or
combine the trial with results from a new trial in a meta-
analysis. However, with a total of 227 events this trial was
not underpowered to detect an effect in the same ballpark
as the Pfizer/BioNTech trial that reported 95% VE. In such
a case it is very interesting to zoom in on the estimate for
the effect, instead of its test.
A standard confidence interval can be seen as an inver-
sion of a hypothesis test: if the null falls outside a two-
sided 90%-confidence interval it can be rejected with a
one-sided type-I error level of α/2= 0.05. In general, the
interval excludes all the values for the parameter that can
be rejected. Similarly, in our context, an anytime-valid
confidence interval excludes all values of the parameter
that can be rejected by an e-value test. So the interval is
essentially tracking a whole range of bets, each against
a different null hypothesis. Figure 3 gives a sequence of
anytime-valid confidence intervals for a random ordering
of the CureVac AG (2021) data, one for each new observed
event or betting round. It shows that the more events we
observe, the more parameters (hazard ratios, or their cor-
responding VEs) we can exclude from the interval. Be-
cause these intervals are valid at any time, once we can
exclude a value, we never have to include it again. So we
also show a sequence of intervals that is the running in-
tersection of all the previous intervals. This of course cru-
cially depends on the ordering, so the one shown for the
CureVac AG (2021) data is just an example, since the or-
dering is not real. Since these intervals are anytime valid,
it is possible to further shrink the intervals by continu-
ing follow-up and observing more events. The coverage
of an anytime-valid confidence sequence—like an e-value
test—has an unlimited horizon.
An ALL-IN meta-analysis confidence interval that is based
on a running intersection is of course only possible in
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Figure 3. 90%-confidence sequence for a random order-
ing of the 83 events in the vaccine group and 145 events
in placebo from the CureVac AG (2021) trial. Note that
the y-axis is on the log scale.
statistics. The confidence interval shown in Figure 3 is
based on the logrank Z-statistic (by repeatedly calculat-
ing it after each event), which can also be a summary
statistic to achieve a single interval that is anytime-valid.
The interval follows from the likelihood ratio of normal
densities from (6) and follows a general recipe for con-
structing confidence sequences from Howard et al. (2021)
where the hazard ratio is obtained by means of the Peto
estimator (Peto, 1987). The same approach can be used
to obtain an ALL-IN meta-analysis confidence interval. A
fixed-effects meta-analysis Z-statistic corresponds to a lo-
grank statistic stratified by trial, and an estimate can be
obtained from such a logrank statistic that Peto (1987)
calls a typical hazard ratio. We discuss this approach a bit
further in the final section.
2 Efficiency
Trials often suffer from recruitment difficulties (McDon-
ald et al., 2006) and find themselves underpowered ac-
cording to their own protocol: when they decide the stop
the recruitment and obtain the final sample size for anal-
ysis, they have a high probability for their test statistic
to fall outside the rejection region they set in advance.
This is exactly the scenario where meta-analysis could
rescue the line of research by combining multiple under-
powered trials. However, the literature on research waste
(Chalmers and Glasziou, 2009) and Evidence-Based Re-
search (Lund et al., 2016) shows that we are not using
the existing evidence base well to design the new trials
needed for conclusion or to interpret new research. ALL-
IN meta-analysis makes this very easy to do. It comes
with a simple notion of the evidence already collected and
what is still needed, and a notion of a new trial’s ability
to provide that: the implied target. The combination of
the two has the capacity to make study design more hon-
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1/4 1 4 16 64 256 1024 4096 16384 65536
€ / LR(160)
Distribution of simulated final betting scores € / LR(160) after 160 events under the alternative hypothesis of 60% VE
Figure 4. (and Figure 5) 1000 simulated sequences of betting scores by round in the FDA game after 160 events
assuming a probability of 0.29 (40/140) for each event to occur in the vaccine group. This is the alternative hypothesis
of 60% VE used to power the CureVac AG (2020) trial at a number of events of 160. The dashed line is the threshold
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Simulated betting scores € / LR(n)  over betting rounds (events) n under the alternative hypothesis of 60% VE
Figure 5. (See above at Figure 4.) The histogram for the final betting scores at the right shows the larger scores above
and the smaller ones at the bottom, which means that if we turn it, it is the mirror image of the histogram in Figure 4.
The dashed line is the threshold 1/α= 40 one-sided and the solid line shows each events’/betting round’s contribution
to the implied target at n = 160 of 112. In this figure, the design has an approximate 79% power to observe a betting
score/e-value larger than 1/α= 40 before 160 events and 72% power at exactly 160 events (better visible in Figure 4).
Note that the y-axis is on a log scale.
est, showing what a trial can add to the existing evidence
base instead of just evaluating a misguided goal to single-
handedly answer a research question.
2.1 The evidence so far and what is still needed
An ALL-IN meta-analysis can set a prospective goal for
conclusion, e.g. α = 0.0025 = 0.052 corresponding to
the level of α required by authorities like the FDA that
ask for two trials at the α = 0.05 level. Following Ville’s
inequality (5) we need a betting score of 1/α = =C400 if
we start with =C1 to reach a conclusion. Because an ALL-
IN meta-analysis combines trials by reinvesting or multi-
plying betting scores, a very simple calculation gives the
betting score we still need at any given point. If an initial
trial is able to reach a score of =C8, any new trial can be de-
signed to multiply that by 50. So on its own, starting with
=C1 instead of =C8, it would need a betting score of =C50
to help the meta-analysis reach =C400. We could evaluate
the sample size of the new trial on its ability to reach 50,
which for a fixed sample size gives the conditional power
of the meta-analysis once the new trial is added. How-
ever, if this second trial also foresees recruitment issues, it
is more difficult to evaluate its planned contribution since
it will probably not be the final trial in the meta-analysis.
For this, Shafer (2021) proposed a new notion for the abil-
ity of a study, not to reach a specific target betting score,
but as a continuous notion of how profitable it can be: the
implied target.
2.2 The ability of a new trial: the implied target
The likelihood ratio summarizes the data not in just
two categories—statistical significant or not statistical
significant—but captures the evidence so far on its way
to a certain threshold. Similarly we propose to not evalu-
ate experimental design as all-or-nothing, but summarize
its ability to build on what is already there and facilitate
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future research. To capture a study’s expected contribu-
tion to a series of studies, we formulate the implied tar-
get from Shafer (2021) as the multiplicative amount with
which the combined evidence is expected to grow if the
study—designed with a certain µmin and sample size n—is











The logarithm appears in equation (8) because the distri-
bution of a likelihood ratio based on n events is very non-
symmetric and heavy tailed, with extremely large likeli-
hood ratios occurring with only small probability (see Fig-
ure 4). So the expectation of the likelihood ratio is drawn
very far from its typical values by these large likelihood
ratios and is not a good expression of what to expect.
The logarithm makes the distribution more symmetric
(asymptotically (for large n) and for normal likelihood ra-
tios even normally distributed), such that the expectation
is a more meaningful summary of the evidence promised
by the study. By exponentiation (exp()) we bring this ex-
pectation back to the scale of the likelihood ratio, such
that it can be interpreted as a betting score or e-value.
In the FDA game the expected growth rate per new event
in the CureVac trial, assuming their effect of minimal in-
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The cumulative contribution of each new event is shown
as the linear line on the log scale in Figure 5. The Cure-
Vac AG (2020, Table 8) design planned a final analysis at
n= 160 events, so their implied target was 1.029454160 ≈
104. In comparison to the target score of =C104 at 160
events, the actual betting score =C1.84 after 83 + 145 =
228 events in the press release is quite disappointing.
Shafer (2021) gives more examples of how betting scores
and implied target help to interpret study results in the
context of study design.
2.3 Honest study design
An implied target does require an honest proposal of the
effect of minimal clinical interest µmin, to evaluate the
merits of the study. In regular power analysis, this pa-
rameter might be tweaked—e.g. setting an unrealistically
large effect—to still argue for the study’s advancement
with only small sample size. Or the smallest effect size
of interest analysis is set after data is observed (Wang
et al., 2018). This behavior is incentivized by the all-or-
nothing character of Neyman-Pearson tests that also make
the power analysis all-or-nothing. If your desired sample
size does not meet the power hoped-for, you need to either
increase it or abandon the study. This aspect of traditional
analyses fully ignores the ideal of cumulative science in
which one study is not expected to single-handedly an-
swer a research question and small increments in knowl-
edge are valuable, as long as they build towards a com-
mon goal. If they use e-values and the ALL-IN framework,
researchers do not have to view their analysis as the final
one, which helps them to evaluate their study more hon-
estly (Lakens, 2021).
3 Collaboration
The Evidence-Based Research Network (Lund et al., 2016)
aims to always inform new research by past results and to
reduce research waste by separating research ideas that
are necessary from those that are wasteful. This is not
easy to do, however. Different communities might have
different notions of necessity or even of what is ethical (a
state of so-called clinical equipoise (Shamy et al., 2020)).
It might therefore be very beneficial to have all those run-
ning new clinical trials in a field collaborate together in
an ALL-IN meta-analysis.
3.1 ALL-IN-META-BCG-CORONA
We ran two ALL-IN meta-analyses during the Covid-19
pandemic with the involvement of seven trials in one and
four in the other. All were designed to study whether
the BCG vaccine, originally developed to protect against
tuberculosis, could protect against Covid-19 (based on a
theory of non-specific immune effects and innate immu-
nity (Netea et al., 2020)). The two meta-analyses study
different populations (healthcare workers and elderly)
and two questions each: the effect of the BCG vaccine
on Covid-19 infection (not necessarily symptomatic) and
the effect on severe Covid-19 (indicated by hospitaliza-
tions). In the following description we will focus on the
analysis of Covid-19 infections in the healthcare workers
population.
ALL-IN-META-BCG-CORONA followed many of the steps
also outlined by Tierney et al. (2021), that we will briefly
discuss here: (1) Meta-analysis design, (2) Systematic
search for trials, (3) Systematic review for trial inclusion
(4) Data upload, and (5) Disseminating results.
(1) Meta-analysis design Early in the project we de-
cided to aim for an IPD meta-analysis on interim data
and wrote our protocols and statistical analysis plans.
This timestamped two important decisions on the meta-
analysis design: the hazard ratio of minimal interest of
0.8 (20% VE) for events of Covid-19 and the level of
α set at 0.0025 so the threshold for the e-value was
at 1/α = 400. For these decisions we set up a meta-
analysis Steering Committee that was still fully blinded
to any results at the time. The design was preregistered
(Van Werkhoven et al., 2021) and all documentation and
a webinar explaining the methodology were made avail-
able on a project website (Ter Schure et al., 2020a).
(2) Systematic search for trials We continuously
searched for trials to include in the meta-analysis. Some
were already known to our Steering committee before we
started. They initiated a BCG trial of their own very early
in the pandemic and shared their protocol with many of
their contacts in the BCG research community. Other tri-
als were found by a repeated systematic search of trial
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Figure 6. Dashboard used to communicate interim results in ALL-IN-META-BCG-CORONA to all data uploaders with a
login. The involved trials were performed in the Netherlands (NL), Denmark (DK), the United States (US), Hungary
(HU), Brazil (BR), France (FR) and Guinea-Bissau/Mozambique (AF). The dashboard is in demo mode and shows fake
data. The option to (de)select trials is for plotting purposes of individual trial e-values; all trials in the dashboard stay
included in the meta e-value, following the decision from the Steering committee on trial inclusion. Note that the y-axis
is on the log scale.
registries. The trials that agreed to join the meta-analysis
were each represented by a member in the Advisory Com-
mittee. Meetings of the Advisory committee were sched-
uled regularly and the trials involved could point us to any
new developments. A major advantage of ALL-IN meta-
analysis here is that the number of trials does not need to
be specified in advance.
(3) Systematic review for trial inclusion We received
external advice from Cochrane Netherlands on trial inclu-
sion based on a thorough risk-of-bias assessment. For this
assessment, each trial shared their protocols, and subse-
quently all Cochrane’s evaluations were shared and dis-
cussed with the Steering committee and Advisory com-
mittee (where trials were usually represented by their PI’s
who were blinded to any trial results). Trials had mul-
tiple opportunities to answer questions—from Cochrane
Netherlands as well as other trials involved—explain their
trial and express other concerns about differences be-
tween the trials included. The Steering Committee made
the final decision on including a trial, before any of that
trial’s results were known to anyone part of the discussion.
The decision of the Steering committee explicitly incorpo-
rated both trial quality and meta-analysis homogeneity.
(4) Data upload Parallel to the discussions on trial in-
clusion, data transfer agreements were signed and data
was shared through a secure upload. Each trial had a data
uploader that was in close contact with the ALL-IN meta-
trial statistician (the first author of this paper) about data
quality. The ALL-IN statistician did not attend the discus-
sion meetings and kept the Steering committee and Ad-
visory committee blinded to any results before each trial
inclusion decision.
(5) Disseminating results Each data-uploader received
a dashboard account with permissions to inspect the
meta-analysis e-value and their own trial contribution.
Their access of interim meta-analysis results in the dash-
board served as a motivator to keep their own trial data
upload up-to-date and to check the sequence of e-values
for errors. Figure 6 shows this dashboard based on a
demo login with fake data (this demo was available for
everyone involved to get an impression). After an initial
period where the data-uploaders could only inspect their
own trial results, they granted each other permission to
inspect all the individual trial contributions. When the
first trials were completed and the meta-analysis was ap-
proaching its conclusion, the results were also presented
to the Advisory and Steering committees. Any interim de-
cisions were planned based on the ALL-IN meta-analysis
e-values, but results were also presented in the context of
power, implied target per trial and confidence sequences.
3.2 Collaborative and bottom-up meta-analysis
In many aspects, our approach agrees with the FAME
proposal from Tierney et al. (2021). FAME argues for
prospective meta-analyses in close collaboration with on-
going trials to achieve the same advantages outlined in
this paper, such as aligning trial characteristics (“mini-
mize heterogeneity”) and reducing publication bias and
“bias [in] both review and meta-analysis methods” intro-
duced by “prior knowledge of trial results” (e.g. accumu-
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lation bias (Ter Schure and Grünwald, 2019)). In align-
ment with the FAME recommendations, ALL-IN-META-
BCG-CORONA was prospectively designed by preregis-
tering an overall effect size of minimal interest and an
α-level. However, ALL-IN meta-analysis in general also
allows for a more bottom-up approach when each trial’s
e-value is based on that trial’s own design (effect size of
minimal interest, see Section 1.4) and trial evidence is
synthesized more loosely without a strict decision rule.
In comparison to FAME, ALL-IN meta-analysis is much
more adaptive. FAME proposes to use conventional meta-
analysis (with a fixed sample size) and optimize the tim-
ing of the meta-analysis “to anticipate the earliest op-
portunity for a potentially definitive meta-analysis”. In
that sense, FAME can only adapt to the speed of recruit-
ment, while ALL-IN allows to adapt to any information
so far including the evidence in the trials and the syn-
thesis of the meta-analysis itself. There is also a statisti-
cal inconsistency in the FAME approach that is concerned
with “striking a balance between maximising the absolute
and relative information size and producing a sufficiently
timely review” but does explicitly state that the last step
of the meta-analysis is to “assess the value of updating
the systematic review and meta-analysis”. A fixed sample-
size statistical analysis should not be reanalyzed using
the same statistical methodology. Any proposal to use
conventional meta-analysis for efficiency purposes risks
accumulation bias (Ter Schure and Grünwald, 2019) be-
cause the timing of the meta-analysis might be driven by
some of the results part of that same analysis. Hence the
best approach is to combine the recommendations from
FAME (Tierney et al., 2021) with statistical approach from
ALL-IN meta-analysis and the spirit of living systematic re-
views.
Collaboration using a dashboard A dashboard for
ALL-IN meta-analysis allows us to spot trends in the accu-
mulating evidence, or allow other stakeholders to mon-
itor. A dashboard like Figure 6 can give access to the
accumulating e-values to those that need to prepare for
crossing a threshold in the near future, e.g. for indepen-
dent data monitoring committees of ongoing trials or for
those considering new trials or preparing to update med-
ical guidelines. On a log-scale, the increase in e-values
is linear (in expectation) and the observed trends can be
estimated, e.g. in Figure 6 as an increase in evidence per
additional calendar day.
For ALL-IN-META-BCG-CORONA, the time unit t in the
definition of LR〈t〉 from (4) was set to calendar days and
the e-values were updated at each calendar day with an
event. The dashboard plots in Figure 6 horizontal lines at
1 for trials that do not observe any events yet: they have
not started betting and are still at their initial investment
of =C1 contributing a neutral amount to the multiplication
meta-e-value. ALL-IN meta-analysis monitors e-values as
events come in, also when they do so from multiple tri-
als simultaneously. In the language of betting, even the
analysis of simultaneous events is considered a sequen-
tial bet. If the bet on the events from one trial pays out
=C4, it multiplies our initial capital by 4, and if the events
from another trial pay out =C5, it does so by a factor 5. Yet
if we actually consider those trials to be consecutive bets,
we reinvest the =C4 from the first into the second, and ob-
tain =C1 · 4 · 5= =C20, as follows from the definition of the
meta-analysis e-value on interim data in (4).
Figure 6 illustrates what going ALL-IN means: the evi-
dence in all studies can be monitored and compared to
the required threshold at any time. The hypothesis test is
carried out by comparing the meta e-value in blue to the
threshold 1/α of 400, plotted as a dotted line. Because the
meta-analysis is anytime and live a conclusion is reached
whenever the e-value sequence passes that threshold. The
synthesis of studies can efficiently lead the decision to stop
recruiting, treat the placebo group or discourage new tri-
als to start, while encouraging inspection of each individ-
ual trial’s contribution to the meta-analysis. Since each
trial’s contribution is a simple multiplication, their compo-
nents can often be conveniently spotted in the agreement
of the shape of the meta-analysis and individual trial lines
in a dashboard like Figure 6 (as long as not too many trials
are contributing simultaneously).
Collaboration in a competitive field or a pandemic
ALL-IN meta-analysis also prevents losing type-I error
control when many trials compete for answers on the
same research question, e.g. in an uncoordinated scien-
tific response to a pandemic. If trials are only evaluated
in isolation and a response follows the first positive re-
sult of a single trial, serious multiple testing issues arise
that inflate the type-I error and result in unreliable infer-
ence and, subsequently, poor decisions. This happens es-
pecially if all trials perform interim analyses on their own,
and a type-I error occurs at an interim analyses before any
other trial results are published to refute it. The exam-
ple dashboard also clearly demonstrates decreased type-
II errors: synthesizing the evidence in a meta-analysis at
interim stages of the trials, and not after trials are com-
pleted, improves the ability to find an effect early. Collab-
oration is indeed much more efficient.
3.3 Fixed-effects and random-effects meta-
analysis
Sutton et al. (2007, p. 2491) note that “in a meta-analysis
with considerable heterogeneity, the impact of a new
(large) study will be (much) less in a random compared to
fixed effect model”. This is due the incorporation of a pa-
rameter in the model that represents the between-study
variation. Also Kulinskaya and Wood (2014) find that
the goal of sequentially updating a random-effect meta-
analysis might involve planning a large number of small
trials to estimate the between-study variance well. Even
if that is considered advisable, a random-effects model re-
sult might still be very difficult to interpret (Riley et al.,
2011). Hence there are various reasons to prefer the
fixed-effects model to monitor evidence efficiently and to
ensure that the trials are sufficiently homogeneous.
Alongside ALL-IN-META-BCG-CORONA we initiated a
second ALL-IN meta-analysis. While the first included tri-
als on healthcare workers, the second included trials in
the elderly. Early in the process, before seeing any data,
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our Steering committee noticed that the two groups could
be very different. Based on a theory of innate and trained
immunity, they expected a different effect of the BCG vac-
cine on the younger immune system of healthcare workers
than on the older immune system in the elderly. It could
even be that the BCG vaccine effect was beneficial in the
ability to fight off Covid-19 in one population but harmful
in the other. In general, the differences between trials can
be in three categories: heterogeneous effects, conflicting
effect and multiple testing.
Heterogeneous effects Our Steering committee de-
cided that to declare success, all included trials in health-
care workers should observe an effect of 20% VE or larger.
If they indeed do, heterogeneity in their effect sizes (e.g.
one 20%, one 50%, one 25%) does not matter for their
joint ability to reject the global null hypothesis of no effect
in all trials. So for testing the global null, trials are al-
lowed to be heterogeneous in where they are in the space
of the alternative hypothesis H1 = {VE : 20% ≤ VE ≤
100%}. For estimation, however, it is not clear what the
ALL-IN confidence interval is estimating if we assume that
the effects in the trials are very different. Still, as a first
summary, a typical effect size (Peto, 1987) might be useful
if we are unable to estimate a random effects model. The
development of confidence sequences for random-effects
meta-analysis is a major goal for future work. We do not,
however, believe that the evidence in a line of research
should be monitored based on whether this interval ex-
cludes the null hypothesis, or whether the e-value cor-
responding to the random-effects null model does: for
testing, the global null is much more natural. Waiting
for a random-effect model to reach a certain threshold is
counter-intuitive, since it might require many small trials
to estimate the between-trial variability instead of focus-
ing on testing the treatment effect. Moreover, the goal of
rejecting the null hypothesis corresponding to this model
can be quite strange. When testing a zero-effect null hy-
pothesis, it assumes that there are true effects of harm
and true effects of benefit among the trials and that their
mean is exactly zero.
Conflicting effects If one of the trials has an effect
smaller than 20% or even a harmful effect, we should an-
ticipate betting scores or e-values that are smaller than 1.
So a meta-analysis multiplication of those e-values would
reduce the evidence available from other trials. If we can
identify groups for which we expect that the trials in each
group have an effect in the same direction and of at least
the minimal size, we can perform separate meta-analyses.
This was the rationale behind grouping healthcare work-
ers and the elderly each in their own ALL-IN-META-BCG-
CORONA analysis.
Multiple testing When our analysis is exploratory, and
we really have no idea how to group the various trials, we
are faced with a multiple testing problem. Note that in
this situation also no conventional meta-analysis method
would be used to test a common null-hypothesis. We won-
der whether any of the trials has the ability to reject the
null hypothesis. In that case, we can divide our initial
investment over the trials, and see if the totality of their
bet achieves a high betting score. Research into this use
of e-values has shown that indeed averaging e-values is
the optimal way to have type-I error control in a standard
multiple testing setting (Vovk and Wang, 2021). We re-
turn to the notion of hedging bets and averaging e-values
in Section 4.
Problems with heterogeneity in meta-analysis are not
tied to the ALL-IN approach and familiar to anyone work-
ing with meta-analysis methods. ALL-IN-META-BCG-
CORONA had the advantage that many of the trials that
started later had drawn inspiration from the protocol of
the first trial. The same sort of alignment of inclusion cri-
teria and outcome definitions might be achieved in other
lines of research as well. Hence close collaboration can be
very important and the promise of an early conclusion of
the research effort might keep a research field motivated
to keep the goals aligned.
4 Communication
We have illustrated that the language of betting can
be useful in interpreting results from an ALL-IN meta-
analysis. Here we argue this further by giving extensions
of our method that are very easily explained in terms of
betting.
4.1 The language of betting for two-sided tests
Our examples so far covered one-sided tests, but those can























to represent a two-sided alternative hypothesis
H1 =

φµ1 : µ1 ≤ µmin(left) or µ1 ≥ µmin(right)
	
.
Such a two-sided test is easy to interpret in the language
of betting. We essentially split our initial investment (e.g.
=C1) between the two sides of the alternative hypothe-
sis (e.g. by betting =C0.50 on one side and =C0.50 on the
other). Any other weighting of the two sides is also pos-
sible and corresponds to a different division of the initial
investment. The crucial thing is that each side tests the
same null hypothesis H0 = {φµ0} and has expectation 1
under the null hypothesis, such that any weighted aver-
age also has expectation 1 and is an e-value. Note that for














Usually one side of the bet is losing and the other is
winning such that we do not want to reinvest (multiply)
across sides but keep them separate for all trials. In our
ALL-IN-META-BCG-CORONA dashboard we also visual-
ized these two sides of the meta-analysis test separately;
in Figure 6 we show only the left-sided test (for benefit)
of the two.
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4.2 The language of betting for co-primary end-
points
Another way to hedge our bets is by considering multi-
ple primary outcomes. In ALL-IN-META-BCG-CORONA,
for example, not only the Covid-19 events were counted,
but Covid-19 hospitalizations as well, as an indicator for
severe disease. We started with α= 0.05 and put 10% on
Covid-19 (α = 0.0025 on each of the two sides of a two-
sided test) and 90% on hospitalisations (α = 0.0225 on
each of the two sides of a two-sided test). So the thresh-
olds to achieve with the e-value for Covid-19 was set at
1/α= 400 and the one for hospitalization at 1/α= 44.44.
A different way to formulate this is that each had to
achieve 1/α = 20, but that the sequence of e-values for
Covid-19 started with an initial investment of =C0.05 for
each side of the two-sided test (and had to multiply by
400 to reach =C20) and that the e-value for hospitalization
started with an initial investment of =C0.45 for each side
(and had to multiply by 44.44 to reach =C20).
There are two ways to consider such a bet on two co-
primary outcomes: separately and combined. If we evalu-
ate the e-values for each primary outcome separately and
reach the threshold with either of the two, we are reject-
ing the null for that outcome. We are doing two separate
tests. If we evaluate the e-values combined, we average
them weighted by their α, just as for the two sides of the
two-sided test. In that case we have similar type-I error
control, but reject the null hypothesis that both are a null
effects in favor of the alternative hypothesis that one of
them is not. Yet we cannot conclude which one is non-
null with the same type-I error since our α level applies to
the combined bet and the individual components to the
averaged bet are essentially lost.
Concluding remarks
The novelty of this paper lies in a new method for meta-
analysis. We do not claim any novelty for the underlying
mathematics, though. The basic methods we describe can
be viewed as relatively minor variations of the anytime-
valid tests that are designed to preserve type-I error under
optional stopping, as designed by H. Robbins and his stu-
dents (Darling and Robbins, 1968; Robbins, 1970). Un-
fortunately and surprisingly, these tests have not caught
on in statistics until a few years ago—right now they are
thriving in work on so-called safe tests, anytime-valid con-
fidence sequences and e-values e.g. Shafer et al. (2011);
Johari et al. (2021); Pace and Salvan (2019); Howard
and Ramdas (2019); Howard et al. (2021); Ramdas et al.
(2020); Vovk and Wang (2021); Shafer (2021); Grün-
wald et al. (2019); Turner et al. (2021); Henzi and Ziegel
(2021). As far as we know, it has never before been
suggested to use such methods in a meta-analysis con-
text. (Group sequential methods, which have originally
also been inspired by the anytime-valid tests, have in turn
spurred developments in meta-analysis, but these are sub-
stantially different from ALL-IN.) Also, the fact that the lo-
grank test can give a likelihood ratio of the type needed for
an anytime-valid test/an ALL-IN meta-analysis is a new
finding described by Ter Schure et al. (2020b).
Likelihood ratios, E-variables and e-values
In this paper we presented betting scores/e-values that
are equivalent to likelihood ratios. In general though,
betting scores and e-values are really generalizations of
likelihood ratios that preserve the properties of likelihood
ratios that give them a prominent role in statistic. Entire
books have been written to advocate for summarizing ev-
idence in observed data by a likelihood ratio (Edwards,
1974; Royall, 1997) and to separate the goal of measuring
evidence from expressing posterior beliefs and making de-
cisions. Likelihood ratios have the property that they can
“favor a true hypothesis over a false one more and more
strongly” and while a likelihood ratio can be misleading,
“strong evidence cannot be misleading very often” (Roy-
all, 1997, p. 14). This latter type-I error control is also
referred to as a universal bound by Royall (1997) and, by
recognizing Ville’s inequality, can be generalized to other
betting scores and e-values.
A betting score € is a random outcome of a bet and its
random variable is an E-variable if it is nonnegative and
for all P ∈ H0, EP[€]≤ 1. For a given outcome of the bet,
the value of such a random variable is the betting score or
e-value. Ville’s inequality relies on the multiplication of
E-variables—forming a test martingale—which also has
expectation smaller than 1 and thus is itself an E-variable.
For the example e-values in this paper, the requirement
on the expectation E0[LR] ≤ 1 holds for a simple null
hypothesis, e.g. H0 = {φ0}.
Apart from likelihood ratios of two simple hypothesis, e-
values can also be defined for more complicated tests—
e.g. a t-test with a nuisance parameter for the variance—
in which case the unit expectation needs to hold not for a
single mean-0-normal distribution with known variance,
but for all mean-0-distributions with any variance. Grün-
wald et al. (2019) shows that it often is possible to con-
struct E-variables for such composite testing problems,
which is why we consider the e-value the right general-
ization of the likelihood ratio.
Anytime-valid confidence sequences
In this paper we briefly presented a confidence sequence
(in Figure 3) for the hazard ratio or VE that was based
on the Gaussian approximation to the logrank statistic
and the Peto (1987) estimator. This estimator can be de-
rived from summary statistics and is therefore still quite
common in meta-analysis as a so-called two-stage method,
although it is advised against for extreme hazard ratios
(Simmonds et al., 2011). Research into other confidence
sequences for the hazard ratio is still ongoing. For other
estimation problems, confidence sequences already have
been thoroughly studied, for example for medians and
other quantiles (Howard and Ramdas, 2019), and odds
ratios (Turner et al., 2021). These have not, however,
been extended to meta-analysis, and especially for the
random-effects meta-analysis model, research into confi-
dence sequences is a major goal of future work.
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Availability in software
The safestats R package (Ly et al., 2021) provides soft-
ware to do an e-value analysis for the t-test, Z-test, lo-
grank test and 2x2-tables. Also functions are available
to calculate the power and implied target for these study
designs. Confidence sequences can be calculated for the
odds ratio in 2x2-tables and the hazard ratio in time-to-
event data.
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Figure 7. Two-sided Z-test against the null hypothesis
H0 = {φ0} observing z = 1.96 with a p-value of 0.05.
The standard way to introduce p-values in introductory
texts is to use a graph like Figure 7 that shades the tail
area of a sampling distribution under the null hypothesis
for an observed test statistic. In Figure 7 the observed test
statistic is a Z-statistic of 1.96, such that the two-sided p-
value is 0.05. The precise definition of this p-value for the
random variable Z and any observation z (e.g. z = 1.96)
is:
p-value(z) = PZ∼φ0 [|Z | ≥ z] (10)
such that for all 0≤ α≤ 1: P0[p-value≤ α] = α,
(11)
with P0 the probability under the null hypothesis. While
explaining-p-by-picture is helpful at first, it also has strong
limitations. For example, if the sample size n is not fixed
in advance but determined by a fixed, a priori known stop-
ping rule (e.g. stop as soon as the first z comes in that
has value > 2.5), then n will itself be random and the
threshold for the test statistic will depend on n; there is
no evident visualization.3 For this reason, it is common in
theoretical statistics to define p-values directly as random
variables that have a uniform distribution under the null.
From (10) and (11) we see that this is compatible with
the introductory approach.
Conservative p-values Defined by property (11), the
standard (strict) p-value can be generalized to a (con-
servative) p-value that does not have a uniform distribu-
tion, but whose distribution is stochastically dominated by
the uniform distribution under the null hypothesis. This
means that the equality in equation (11) is replaced by an
inequality:
P0[p-value≤ α]≤ α. (12)
3An exception is the case in which there are just two possible sample
sizes, n1 and n2, with the rule for choosing between n1 and n2 based on
the first n1 data points z
(n1) given (e.g. stop if z(n1) > 2.5, continue oth-
erwise). We can then specify a bivariate distribution and evaluate the
tail area for the combined observations (e.g. (z(n1), z(n2))). This is some-
times illustrated in introductory texts on group-sequential methods, but
cannot be extended beyond this (3D) bivariate case.
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For such conservative p-values, it still holds that, for any
fixed significance level α, the test that rejects if p ≤ α has
type-I error at most α. The inequality is thus in the right
direction to preserve type-I error guarantees.
Our first observation is very simple: for any fixed n, the
likelihood ratio LR(n) is an inverse-conservative p-value
for samples of that size n, i.e. (12) holds with ‘p-value’
set to 1/LR(n). However, simply viewing LRs as inverse
conservative p-values is not nearly doing them sufficient
justice. A better (yet still incomplete) comparison is to
‘anytime-valid p-values’, a terminology that stems from
(Johari et al., 2017, 2021). Whereas standard p-values
only make sense for an a priori given, fixed sample size
n or a priori given, fixed stopping rule, anytime-valid p-
values are really sequences p′1, p
′
2, . . ., one for each sam-
ple size n. Even if the stopping rule for determining n is
unknown in advance, or unclear, or greedy (‘stop at first
n such that pn ≤ α’), the type-I error guarantee is pre-
served. It turns out that the inverse of the LRs as defined
for ALL-IN meta-analysis can be viewed in this way: the
sequence (1/LR(1), 1/LR(2), . . .) as defined in Section 1 is
a sequence of anytime-valid p-values.
B R Code for calculations, simulations and
plots
R code for the calculations, simulations and plots in this
paper can be found on the Open Science Framework
(Ter Schure, 2021, https://osf.io/d9jny/), includ-
ing:
• Settings of the FDA game
• Pfizer/BioNtech results in the FDA game
• CureVac results in terms of confidence interval and
the FDA game
• Plotting the FDA game betting scores under the null
hypothesis (Figure 1)
• Plotting the expected sample size for various strate-
gies in the FDA game (Figure 2)
• Plotting the anytime-valid confidence sequence for a
random ordering of the CureVac data (Figure 3)
• Plotting the implied target of the CureVac design in
the FDA game (Figure 4 & 5)
• Plotting a p-value of 0.05 (Figure 6; Appendix)
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